PTGS2 and neoplasm: Further in vivo studies using this [58,59,60,61] and other tumor models as glioblastoma [62,63,64,65], secondary bone tumors [66], and lung A549 tumor xenografts [67] unraveled in the following years radiosensitization also for other COX-2 selective inhibitors such as nimesulide [67], NS-398 [59], celecoxib [58,63,64,66], and the celecoxib derivatives E-6087, E-6132 [65], SC-′236 [60,61,62] (reviewed in part in [39,56,68]).